Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other 1Head & Neck 1

Conditions

Xerostomia 1Squamous Cell Carcinoma of Head and Neck 1Sexual Dysfunction, Physiological 1Radiation Injuries 1Obesity 1Neurotoxicity Syndromes 1Mucositis 1Head and Neck Neoplasms 1Fatigue 1Eunuchism 1Erectile Dysfunction 1Chemotherapy-induced Peripheral Neuropathy 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Radiotherapy 4Radiation 3Cisplatin 3Amifostine 2pegfilgrastim 1Surgical Procedures, Operative 1Selenomethionine 1Paclitaxel 1Oral Hygiene 1Low-Level Light Therapy 1Lansoprazole 1Granulocyte Colony-Stimulating Factor 1Fluorouracil 1Filgrastim 1Fibroblast Growth Factor 7 1Docetaxel 1Dexlansoprazole 1Carboplatin 1Biotene 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Xerostomia × Carboplatin × Other × Clear all
NCT00095927 2017-01-04

Randomized Amifostine For SCCHN

Dana-Farber Cancer Institute

Phase 2 Completed
58 enrolled
Head & NeckOther

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Radiation Injuries, Xerostomia, Mucositis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡